News

Authors: M F Botteman, M Meijboom, I Foley, J M Stephens, Y M Chen, S Kaura Published: European Journal of Health Economics, 2011 View publication Background The use of zoledronic acid (ZOL)...

Authors: J A Carter, A D Joshi, S Kaura, M F Botteman Published: Pharmacoeconomics, 2012 View publication Abstract Bisphosphonates reduce the risk of skeletal-related events (SREs; i.e. spinal cord compression, pathological fracture,...

Authors: J A Carter, M F Botteman Published: Expert Review Pharmacoeconomics and Outcomes Research, 2012 View publication Abstract Zoledronic acid is the only bisphosphonate approved for the prevention or delay of skeletal-related...

Authors: X Gao, D Wendling, M F Botteman, J A Carter, S Rao, M Cifaldi Published: Journal of Medical Economists, 2012 View publication Objective To assess concomitant extra-articular manifestation (EAM) rates in...

Authors: S J Snedecor, J A Carter, S Kaura, M F Botteman Published: Clinical Therapy, 2012 View publication Background Denosumab has been approved in the United States for the prevention of skeletal-related...

Authors: S J Snedecor, J A Carter, S Kaura, M F Botteman Published: Journal of Medical Economists, 2012 View publication Objective Denosumab has been approved in the US for skeletal-related event (SRE)...

Authors: J A Carter, X Ji, M F Botteman Published: Expert Review of Pharmacoeconomics and Outcomes Research, 2013 View publication Abstract Despite effective skeletal-related event (SRE)-limiting therapies such as zoledronic acid and...

Authors: Y Wan, X Gao, S Mehta, Z Wang, C Faria, L Schwartzberg Published: Journal of Medical Economists, 2013 View publication Objective To compare the indirect costs of productivity loss between metastatic...

Authors: A M Zeidan; D Mahmoud, I T Kucmin-Bemelmans, C J Alleman, M Hensen, B Skikne, B D Smith Published: Expert review of hematology, 2016 View publication Background The economic burden associated...